EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma

Jiri Polivka, Mohamed A Gouda iD, Mahyar Sharif iD, Martin Pesta iD, Helen Huang, Inka Treskova, Vlastimil Woznica, Jindra Windrichova, Katerina Houfkova, Radek Kucera, Tomas Fikrle, Jan Ricar und 3 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jiri Polivka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, S100 Calcium Binding Protein beta Subunit, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by LTAUSA19080 program, INTEREXCELLENCE, INTER-ACTION, Ministry of Education, Youth and Sports of the Czech Republic; by Cooperation Pr….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma is the most aggressive skin cancer with ability to recur also after early‐stage tumor surgery. The aim was to identify early‐stage melanoma patients at high risk of recurrence using liquid biopsy, estimating of mutated BRAF ctDNA and the level of tumor marker S100B in plasma.

Methods

Eighty patients were enrolled in the study. BRAF V600E mutation was determined in FFPE tissue and plasma samples using ultrasensitive ddPCR with pre‐amplification. The level of S100B was determined in plasma by immunoassay chemiluminescent method.

Results

The best prediction of melanoma recurrence after surgery was observed in patients with combined high level of S100B (S100B high ) and ctDNA BRAFV600E (BRAF mut ) in preoperative (57.1% vs. 12.5%, p = 0.025) as well as postoperative blood samples (83.3% vs. 14.3%, resp., p = 0.001) in comparison with low S100B and BRAF wild‐type. Similarly, patients with preoperative and postoperative S100B high and BRAF mut experienced worse prognosis (DFI p = 0.05, OS p = 0.131 and DFI p = 0.001, OS = 0.001, resp.).

Conclusion

We observed the benefit of the estimation of combination of S100B and ctDNA BRAF mut in peripheral blood for identification of patients at high risk of recurrence and unfavorable prognosis. Significance There is still no general consensus on molecular markers for deciding the appropriateness of adjuvant treatment of early‐stage melanoma. We have shown for the first time that the combined determination of the ctDNA BRAF mut oncogene (liquid biopsy) and the high level of tumor marker S100B in pre‐ and postoperative plasma samples can identify patients with the worst prognosis and the highest risk of tumor recurrence. Therefore, modern adjuvant therapy would be appropriate for these patients with resectable melanoma, regardless of disease stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMelanomaS100 Calcium Binding Protein beta SubunitBiomarkers, TumorMutationSkin NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultNeoplasm StagingPrognosisLiquid BiopsyAged, 80 and overPredictive Value of Tests

Stichwörter der Autor:innen

BRAF V600ES100BctDNAddPCRmelanoma

Substanzen

Proto-Oncogene Proteins B-rafS100 Calcium Binding Protein beta SubunitS100B protein, humanBiomarkers, TumorBRAF protein, human

Autor:innen und Institutionen

  • Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic.
  • Department of Immunochemical Diagnostics, University Hospital Pilsen, Pilsen, Czech Republic.

ORCID-Profile: Mohamed A Gouda, Mahyar Sharif, Martin Pesta

Förderung

  • This work was supported by LTAUSA19080 program, INTEREXCELLENCE, INTER-ACTION, Ministry of Education, Youth and Sports of the Czech Republic; by Cooperation Pr…

Zitieren

APA

Polivka, J., Gouda, M. A., Sharif, M., Pesta, M., Huang, H., Treskova, I., Woznica, V., Windrichova, J., Houfkova, K., Kucera, R., Fikrle, T., Ricar, J., Pivovarcikova, K., Topolcan, O., & Janku, F. (2024). Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma. Cancer Medicine. https://doi.org/10.1002/cam4.70313

Vancouver

Polivka J, Gouda MA, Sharif M, Pesta M, Huang H, Treskova I, et al. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma. Cancer Medicine. 2024. doi:10.1002/cam4.70313

BibTeX
@article{Polivka2024,
  author = {Polivka, Jiri and Gouda, Mohamed A and Sharif, Mahyar and Pesta, Martin and Huang, Helen and Treskova, Inka and Woznica, Vlastimil and Windrichova, Jindra and Houfkova, Katerina and Kucera, Radek and Fikrle, Tomas and Ricar, Jan and Pivovarcikova, Kristyna and Topolcan, Ondrej and Janku, Filip},
  title = {Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70313}
}
Kostenlos starten →